China Genetic Testing Market Analysis Report 2022: An $8 Billion Market by 2027 Featuring BGI, Berry Genomics, Daan Gene, WuXi NextCODE, Annoroad Gene Technology, & WuXi PharmaTech – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “China Genetic Testing Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” report has been added to ResearchAndMarkets.com’s offering.

The China genetic testing market size reached US$ 3.1 Billion in 2021. Looking forward, the market to reach US$ 8.0 Billion by 2027, exhibiting a CAGR of 17.12% during 2021-2027.

Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Genetic testing is becoming popular in China. It may benefit many different interest groups, such as individuals and families with a history of genetic disorder, pregnant women, employers, and health or life insurance. This market is currently driven by a number of factors such as rising awareness regarding the benefits of genetic testing, availability of direct to consumer tests and increasing incidences of genetic disorders.

Over the past few years, there has been a significant rise in the awareness levels regarding the benefits of genetic testing in China. Genetic testing provides various technologies that help in the early detection of various chronic diseases and ensures its treatment and prevention.

Moreover, a rise in the availability of Direct to consumer tests (DTC) which has increased the convenience and accessibility of such tests is also creating a positive impact in the growth of the market. Moreover, In October, 2015, China announced that the iconic one-child policy had finally been replaced by a universal two-child policy.

This is expected to increase the number of babies born each year and create a positive impact on the demand of the new born genetic testing segment. Other major factors that are expected to drive this market include growing middle class, aging population, and expanding healthcare system.

Key Questions Answered in This Report:

• How has the China genetic testing market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the China genetic testing market?
• What is the breakup of the China genetic testing market based on the test type?
• What is the breakup of the China genetic testing market based on the disease?
• What is the breakup of the China genetic testing market based on the technology?
• What is the breakup of the China genetic testing market based on the service provider?
• What is the breakup of the China genetic testing market based on the testing sample?
• What are the various stages in the value chain of the China genetic testing market?
• What are the key provinces in the China genetic testing market?
• What are the key driving factors and challenges in the China genetic testing market?
• What is the structure of China genetic testing industry and who are the key players?
• What is the degree of competition in the China genetic testing market?

Competitive Landscape:

The report has also examined the competitive landscape of the China genetic testing market. Some of the major players include:

• BGI
• Berry Genomics Co. ltd.
• Daan Gene Co. Ltd
• WuXi NextCODE
• Annoroad Gene Technology Co. Ltd.
• WuXi PharmaTech

Key Market Segmentation:

Breakup by Test Type:

Based on the test type, the market has been divided as prenatal testing, newborn testing, diagnostic testing, carrier testing, predictive or presymptomatic testing and others. Amongst these, prenatal testing represents the biggest segment.

• Prenatal Testing
• Carrier Testing
• New Born Testing
• Predictive/Presymptomatic Testing
• Diagnostic Testing
• Others

Breakup by Disease:

Based on the disease, the market has been segmented into cancer, down syndrome, thalassemia and others. Amongst these, cancer represents the biggest segment.

• Cancer
• Down Syndrome
• Thalassemia
• Others

Breakup by Technology:

Based on the technology, the market has been segmented into cytogenetic, biochemical and molecular. Biochemical currently represents the biggest segment.

• Biochemical
• Molecular
• Cytogenetic

Breakup by Service Provider:

Based on the service provider, the market has been segmented into hospital based Laboratories, independent laboratories and specialty clinics. Amongst these, hospital based Laboratories has the largest share.

• Hospital Based Laboratories
• Independent Laboratories
• Specialty Clinics

Breakup by Testing Sample:

• Blood
• Saliva
• Hair
• Others

For more information about this report visit https://www.researchandmarkets.com/r/5ftsvi

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900